KPC Pharmaceuticals, Inc.

Shanghai Stock Exchange 600422.SS

KPC Pharmaceuticals, Inc. Gross Profit Margin for the year ending December 31, 2023: 44.26%

KPC Pharmaceuticals, Inc. Gross Profit Margin is 44.26% for the year ending December 31, 2023, a 6.62% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

KPC Pharmaceuticals, Inc. Gross Profit Margin for the year ending December 31, 2022 was 41.52%, a 0.52% change year over year.
KPC Pharmaceuticals, Inc. Gross Profit Margin for the year ending December 31, 2021 was 41.30%, a -5.79% change year over year.
KPC Pharmaceuticals, Inc. Gross Profit Margin for the year ending December 31, 2020 was 43.84%, a -9.94% change year over year.
KPC Pharmaceuticals, Inc. Gross Profit Margin for the year ending December 31, 2019 was 48.68%, a -2.42% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Shanghai Stock Exchange: 600422.SS

KPC Pharmaceuticals, Inc.

CEO	Mr. Sun Zhi Qiang
IPO Date	Dec. 6, 2000
Location	China
Headquarters	No.166 Keyi Road
Employees	5,051
Sector	Health Care
Industries Pharmaceuticals

Description

KPC Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People's Republic of China and internationally. It offers artemether, panax notoginseng, and gastrodine series drugs, as well as Chinese medicines and ethnic drugs under the Luotai, Tianxuanqing, Artemedine, Artem, and Arco brand names for treating cardio-cerebral-vascular and nervous system diseases, as well as malaria. The company also provides Dai medicines; antibiotics, chemical medicinal raw materials, chemical pharmaceutical preparations, traditional Chinese medicinal materials, biological products, biochemical drugs, and health foods; Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, and Ribavirin spray products; glycyrrhizic acid; and GLP-1, a long-acting hypoglycemic drug. It markets artemisinin antimalarials, generic drugs, and medical apparatus. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals, Inc. was founded in 1951 and is based in Kunming, the People's Republic of China.

Key trends

Past 5 years